Global Breast Recurrence Score Test Market

Breast Recurrence Score Test Comprehensive Study by Type (First-Generation Test, Second Generation Test), Indication (Stage I Invasive Breast Cancer, Stage II Invasive Breast Cancer, Estrogen Receptor-Positive Cancer, Lymph Node-Negative Breast Cancer), End-User (Hospitals, Speciality Cancer Centers, Advanced Diagnostic Centers, Others) Players and Region - Global Market Outlook to 2027

Breast Recurrence Score Test Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Breast Recurrence Score Test?
Breast cancer is a type of cancer that develops in the cells of the breast and is most common in women. After lung cancer, breast cancer is the second largest cause of death in women. The breast recurrence score test is a sort of genome test that examines the activity of genes linked to breast cancer. The breast recurrence score test is helpful in determining the best treatment plan for breast cancer. The impact and progress of chemotherapy on the patient are also revealed by the breast recurrence score test. Breast cancer risk can be estimated early on using a breast recurrence score test, and action can be taken accordingly. This breast recurrence score test is done on breast cancer tissue that was taken during the surgery.The market for breast recurrence score tests is predicted to grow as the prevalence of breast cancer rises. Breast recurrence score test market expansion is boosted by high efficiency and rapid results. The prognostic aspect of the test boosts the market for breast recurrence score tests. Breast recurrence score test market expansion will be aided by increased breast cancer awareness and investment. The growth of the breast recurrence score test market will be fueled by the ease of reimbursement policies.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledEXACT Sciences Corporation (United States), OncoQuest Inc (Canada), Roche Diagnostics (Switzerland), Braster (Poland), Bremed (China), Forward Science Technologies (United States), Guided Therapeutics (United States), Varian Medical Systems (United States), PWB Health (United Kingdom) and Zilico Medical Diagnostics (United Kingdom)


The study covers a detailed analysis segmented by key business segments i.e. by type (First-Generation Test and Second Generation Test) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Breast Recurrence Score Test market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Breast Recurrence Score Test market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are EXACT Sciences Corporation (United States), OncoQuest Inc (Canada), Roche Diagnostics (Switzerland), Braster (Poland), Bremed (China), Forward Science Technologies (United States), Guided Therapeutics (United States), Varian Medical Systems (United States), PWB Health (United Kingdom) and Zilico Medical Diagnostics (United Kingdom).

Market Overview:
November 2019 – Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company

Market Trend
Development in Oncology Treatment drugs and Various Governments Initiatives to Increase Awareness and Investment
Restraints
  • High Treatment Cost

Opportunities
Increase Investment in R&D in Cancer Treatment, Rise in The Number of Diagnostic Laboratories Advanced Diagnostic Centres and Ease in Reimbursement Policies Increases the Rate of Breast Cancer Diagnostics Resulting in Significant Growth Rate

Key highlights of the Global Breast Recurrence Score Test market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the Breast Recurrence Score Test market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global Breast Recurrence Score Test market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Breast Recurrence Score Test Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Breast Recurrence Score Test market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Breast Recurrence Score Test market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Medical Research Institutes, Pharmaceutical Companies, Governmental bodies, Service Providers and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • First-Generation Test
  • Second Generation Test
By Indication
  • Stage I Invasive Breast Cancer
  • Stage II Invasive Breast Cancer
  • Estrogen Receptor-Positive Cancer
  • Lymph Node-Negative Breast Cancer

By End-User
  • Hospitals
  • Speciality Cancer Centers
  • Advanced Diagnostic Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Breast Cancer
      • 3.2.2. Increasing Awareness and Spending on Health
    • 3.3. Market Challenges
      • 3.3.1. Less Advanced Technology and Diagnostic Rate in Certain Countries
    • 3.4. Market Trends
      • 3.4.1. Development in Oncology Treatment drugs
      • 3.4.2. Various Governments Initiatives to Increase Awareness and Investment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Breast Recurrence Score Test, by Type, Indication, End-User and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Breast Recurrence Score Test (Value)
      • 5.2.1. Global Breast Recurrence Score Test by: Type (Value)
        • 5.2.1.1. First-Generation Test
        • 5.2.1.2. Second Generation Test
      • 5.2.2. Global Breast Recurrence Score Test by: Indication (Value)
        • 5.2.2.1. Stage I Invasive Breast Cancer
        • 5.2.2.2. Stage II Invasive Breast Cancer
        • 5.2.2.3. Estrogen Receptor-Positive Cancer
        • 5.2.2.4. Lymph Node-Negative Breast Cancer
      • 5.2.3. Global Breast Recurrence Score Test by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Speciality Cancer Centers
        • 5.2.3.3. Advanced Diagnostic Centers
        • 5.2.3.4. Others
      • 5.2.4. Global Breast Recurrence Score Test Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Breast Recurrence Score Test: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. EXACT Sciences Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. OncoQuest Inc (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche Diagnostics (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Braster (Poland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bremed (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Forward Science Technologies (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Guided Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Varian Medical Systems (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. PWB Health (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Zilico Medical Diagnostics (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Breast Recurrence Score Test Sale, by Type, Indication, End-User and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Breast Recurrence Score Test (Value)
      • 7.2.1. Global Breast Recurrence Score Test by: Type (Value)
        • 7.2.1.1. First-Generation Test
        • 7.2.1.2. Second Generation Test
      • 7.2.2. Global Breast Recurrence Score Test by: Indication (Value)
        • 7.2.2.1. Stage I Invasive Breast Cancer
        • 7.2.2.2. Stage II Invasive Breast Cancer
        • 7.2.2.3. Estrogen Receptor-Positive Cancer
        • 7.2.2.4. Lymph Node-Negative Breast Cancer
      • 7.2.3. Global Breast Recurrence Score Test by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Speciality Cancer Centers
        • 7.2.3.3. Advanced Diagnostic Centers
        • 7.2.3.4. Others
      • 7.2.4. Global Breast Recurrence Score Test Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Breast Recurrence Score Test: by Type(USD Million)
  • Table 2. Breast Recurrence Score Test First-Generation Test , by Region USD Million (2016-2021)
  • Table 3. Breast Recurrence Score Test Second Generation Test , by Region USD Million (2016-2021)
  • Table 4. Breast Recurrence Score Test: by Indication(USD Million)
  • Table 5. Breast Recurrence Score Test Stage I Invasive Breast Cancer , by Region USD Million (2016-2021)
  • Table 6. Breast Recurrence Score Test Stage II Invasive Breast Cancer , by Region USD Million (2016-2021)
  • Table 7. Breast Recurrence Score Test Estrogen Receptor-Positive Cancer , by Region USD Million (2016-2021)
  • Table 8. Breast Recurrence Score Test Lymph Node-Negative Breast Cancer , by Region USD Million (2016-2021)
  • Table 9. Breast Recurrence Score Test: by End-User(USD Million)
  • Table 10. Breast Recurrence Score Test Hospitals , by Region USD Million (2016-2021)
  • Table 11. Breast Recurrence Score Test Speciality Cancer Centers , by Region USD Million (2016-2021)
  • Table 12. Breast Recurrence Score Test Advanced Diagnostic Centers , by Region USD Million (2016-2021)
  • Table 13. Breast Recurrence Score Test Others , by Region USD Million (2016-2021)
  • Table 14. South America Breast Recurrence Score Test, by Country USD Million (2016-2021)
  • Table 15. South America Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 16. South America Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 17. South America Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 18. Brazil Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 19. Brazil Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 20. Brazil Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 21. Argentina Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 22. Argentina Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 23. Argentina Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 24. Rest of South America Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 25. Rest of South America Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 26. Rest of South America Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 27. Asia Pacific Breast Recurrence Score Test, by Country USD Million (2016-2021)
  • Table 28. Asia Pacific Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 29. Asia Pacific Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 30. Asia Pacific Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 31. China Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 32. China Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 33. China Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 34. Japan Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 35. Japan Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 36. Japan Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 37. India Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 38. India Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 39. India Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 40. South Korea Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 41. South Korea Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 42. South Korea Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 43. Taiwan Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 44. Taiwan Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 45. Taiwan Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 46. Australia Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 47. Australia Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 48. Australia Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 52. Europe Breast Recurrence Score Test, by Country USD Million (2016-2021)
  • Table 53. Europe Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 54. Europe Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 55. Europe Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 56. Germany Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 57. Germany Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 58. Germany Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 59. France Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 60. France Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 61. France Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 62. Italy Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 63. Italy Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 64. Italy Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 65. United Kingdom Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 66. United Kingdom Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 67. United Kingdom Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 68. Netherlands Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 69. Netherlands Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 70. Netherlands Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 71. Rest of Europe Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 72. Rest of Europe Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 73. Rest of Europe Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 74. MEA Breast Recurrence Score Test, by Country USD Million (2016-2021)
  • Table 75. MEA Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 76. MEA Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 77. MEA Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 78. Middle East Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 79. Middle East Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 80. Middle East Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 81. Africa Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 82. Africa Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 83. Africa Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 84. North America Breast Recurrence Score Test, by Country USD Million (2016-2021)
  • Table 85. North America Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 86. North America Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 87. North America Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 88. United States Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 89. United States Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 90. United States Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 91. Canada Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 92. Canada Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 93. Canada Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 94. Mexico Breast Recurrence Score Test, by Type USD Million (2016-2021)
  • Table 95. Mexico Breast Recurrence Score Test, by Indication USD Million (2016-2021)
  • Table 96. Mexico Breast Recurrence Score Test, by End-User USD Million (2016-2021)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Breast Recurrence Score Test: by Type(USD Million)
  • Table 108. Breast Recurrence Score Test First-Generation Test , by Region USD Million (2022-2027)
  • Table 109. Breast Recurrence Score Test Second Generation Test , by Region USD Million (2022-2027)
  • Table 110. Breast Recurrence Score Test: by Indication(USD Million)
  • Table 111. Breast Recurrence Score Test Stage I Invasive Breast Cancer , by Region USD Million (2022-2027)
  • Table 112. Breast Recurrence Score Test Stage II Invasive Breast Cancer , by Region USD Million (2022-2027)
  • Table 113. Breast Recurrence Score Test Estrogen Receptor-Positive Cancer , by Region USD Million (2022-2027)
  • Table 114. Breast Recurrence Score Test Lymph Node-Negative Breast Cancer , by Region USD Million (2022-2027)
  • Table 115. Breast Recurrence Score Test: by End-User(USD Million)
  • Table 116. Breast Recurrence Score Test Hospitals , by Region USD Million (2022-2027)
  • Table 117. Breast Recurrence Score Test Speciality Cancer Centers , by Region USD Million (2022-2027)
  • Table 118. Breast Recurrence Score Test Advanced Diagnostic Centers , by Region USD Million (2022-2027)
  • Table 119. Breast Recurrence Score Test Others , by Region USD Million (2022-2027)
  • Table 120. South America Breast Recurrence Score Test, by Country USD Million (2022-2027)
  • Table 121. South America Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 122. South America Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 123. South America Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 124. Brazil Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 125. Brazil Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 126. Brazil Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 127. Argentina Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 128. Argentina Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 129. Argentina Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 130. Rest of South America Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 131. Rest of South America Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 132. Rest of South America Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 133. Asia Pacific Breast Recurrence Score Test, by Country USD Million (2022-2027)
  • Table 134. Asia Pacific Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 135. Asia Pacific Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 136. Asia Pacific Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 137. China Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 138. China Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 139. China Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 140. Japan Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 141. Japan Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 142. Japan Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 143. India Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 144. India Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 145. India Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 146. South Korea Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 147. South Korea Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 148. South Korea Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 149. Taiwan Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 150. Taiwan Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 151. Taiwan Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 152. Australia Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 153. Australia Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 154. Australia Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 155. Rest of Asia-Pacific Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 156. Rest of Asia-Pacific Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 157. Rest of Asia-Pacific Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 158. Europe Breast Recurrence Score Test, by Country USD Million (2022-2027)
  • Table 159. Europe Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 160. Europe Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 161. Europe Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 162. Germany Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 163. Germany Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 164. Germany Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 165. France Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 166. France Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 167. France Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 168. Italy Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 169. Italy Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 170. Italy Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 171. United Kingdom Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 172. United Kingdom Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 173. United Kingdom Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 174. Netherlands Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 175. Netherlands Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 176. Netherlands Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 177. Rest of Europe Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 178. Rest of Europe Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 179. Rest of Europe Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 180. MEA Breast Recurrence Score Test, by Country USD Million (2022-2027)
  • Table 181. MEA Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 182. MEA Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 183. MEA Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 184. Middle East Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 185. Middle East Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 186. Middle East Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 187. Africa Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 188. Africa Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 189. Africa Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 190. North America Breast Recurrence Score Test, by Country USD Million (2022-2027)
  • Table 191. North America Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 192. North America Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 193. North America Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 194. United States Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 195. United States Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 196. United States Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 197. Canada Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 198. Canada Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 199. Canada Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 200. Mexico Breast Recurrence Score Test, by Type USD Million (2022-2027)
  • Table 201. Mexico Breast Recurrence Score Test, by Indication USD Million (2022-2027)
  • Table 202. Mexico Breast Recurrence Score Test, by End-User USD Million (2022-2027)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Breast Recurrence Score Test: by Type USD Million (2016-2021)
  • Figure 5. Global Breast Recurrence Score Test: by Indication USD Million (2016-2021)
  • Figure 6. Global Breast Recurrence Score Test: by End-User USD Million (2016-2021)
  • Figure 7. South America Breast Recurrence Score Test Share (%), by Country
  • Figure 8. Asia Pacific Breast Recurrence Score Test Share (%), by Country
  • Figure 9. Europe Breast Recurrence Score Test Share (%), by Country
  • Figure 10. MEA Breast Recurrence Score Test Share (%), by Country
  • Figure 11. North America Breast Recurrence Score Test Share (%), by Country
  • Figure 12. Global Breast Recurrence Score Test share by Players 2021 (%)
  • Figure 13. Global Breast Recurrence Score Test share by Players (Top 3) 2021(%)
  • Figure 14. Global Breast Recurrence Score Test share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. EXACT Sciences Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 17. EXACT Sciences Corporation (United States) Revenue: by Geography 2021
  • Figure 18. OncoQuest Inc (Canada) Revenue, Net Income and Gross profit
  • Figure 19. OncoQuest Inc (Canada) Revenue: by Geography 2021
  • Figure 20. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Roche Diagnostics (Switzerland) Revenue: by Geography 2021
  • Figure 22. Braster (Poland) Revenue, Net Income and Gross profit
  • Figure 23. Braster (Poland) Revenue: by Geography 2021
  • Figure 24. Bremed (China) Revenue, Net Income and Gross profit
  • Figure 25. Bremed (China) Revenue: by Geography 2021
  • Figure 26. Forward Science Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 27. Forward Science Technologies (United States) Revenue: by Geography 2021
  • Figure 28. Guided Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Guided Therapeutics (United States) Revenue: by Geography 2021
  • Figure 30. Varian Medical Systems (United States) Revenue, Net Income and Gross profit
  • Figure 31. Varian Medical Systems (United States) Revenue: by Geography 2021
  • Figure 32. PWB Health (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. PWB Health (United Kingdom) Revenue: by Geography 2021
  • Figure 34. Zilico Medical Diagnostics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. Zilico Medical Diagnostics (United Kingdom) Revenue: by Geography 2021
  • Figure 36. Global Breast Recurrence Score Test: by Type USD Million (2022-2027)
  • Figure 37. Global Breast Recurrence Score Test: by Indication USD Million (2022-2027)
  • Figure 38. Global Breast Recurrence Score Test: by End-User USD Million (2022-2027)
  • Figure 39. South America Breast Recurrence Score Test Share (%), by Country
  • Figure 40. Asia Pacific Breast Recurrence Score Test Share (%), by Country
  • Figure 41. Europe Breast Recurrence Score Test Share (%), by Country
  • Figure 42. MEA Breast Recurrence Score Test Share (%), by Country
  • Figure 43. North America Breast Recurrence Score Test Share (%), by Country
List of companies from research coverage that are profiled in the study
  • EXACT Sciences Corporation (United States)
  • OncoQuest Inc (Canada)
  • Roche Diagnostics (Switzerland)
  • Braster (Poland)
  • Bremed (China)
  • Forward Science Technologies (United States)
  • Guided Therapeutics (United States)
  • Varian Medical Systems (United States)
  • PWB Health (United Kingdom)
  • Zilico Medical Diagnostics (United Kingdom)
Select User Access Type

Key Highlights of Report


Jul 2022 163 Pages 71 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Breast Recurrence Score Test Market Quantitative research analysis
Global Breast Recurrence Score Test Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Breast Recurrence Score Test Market is heading robustly to achieve new growth cycle.
The Concentration Rate of Global Breast Recurrence Score Test market is dominated by United States Players and may generate healthy valuation by 2027.
  • Rising Prevalence of Breast Cancer
  • Increasing Awareness and Spending on Health
dominated the Breast Recurrence Score Test market. This is attributable to growing trend of "Development in Oncology Treatment drugs "

Know More About Global Breast Recurrence Score Test Market Report?

Have a Query? Click Here

Other Related Reports

Pulsechase Analysis Comprehensive Study by Type (Vector, Fluorescent substrate, Non-fluorescent block compound, Others), Application (Proteomics, Nanotechnology-Proteomics, Others) Players and Region...
$ 3500
Erdheim Chester Disease Treatment Comprehensive Study by Application (Immunotherapy, Chemotherapy), Distribution Channel (Hospital, Specialty Clinics, Hospital Pharmacy, Online Pharmacy, Retail Pharm...
$ 3450
Bioreactor Flask Comprehensive Study by End Users (Biopharmaceutical Companies, CROs, Academic and Research Institutes, Others), Capacity (50 ml, 350ml, 600 ml, 1000ml, Others), Usages (Disposable, R...
$ 3500
Sperm Function Testing Comprehensive Study by Type (Andro Scope-Basic, Andro Scope-Advanced, Sperm Counting Chamber, Collection Room Device, Androbox, Others), End-User (Hospitals, Sperm Lab, Clinica...
$ 3800
Prothrombin Time Testing Comprehensive Study by Type (Instruments, Consumables, Systems), Application (Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Prothrombin Time (PT), Partial...
$ 3750
At-Home Fitness Equipment Comprehensive Study by Type (Treadmills, Elliptical Machines, Stationary Cycles, Rowing Machines, Strength Training Equipment, Others), Price Range (Low, Medium, High), Dist...
$ 3650